PeptideStack
5.2kquestions
20kanswers
220users

Is STEP 4 a fair comparison of semaglutide against its comparator arm?

Asked 5 Mar 2026Modified 5 months agoViewed 4.8k times
This question was closed as primarily opinion-based.Closed 14 Mar 2026. Answers already posted are preserved; new answers are not accepted. Questions here need a factual basis on which they can be answered.
23

Numbers first: STEP 4 · semaglutide.

I am asking for verification rather than opinion, ideally with something I can read myself.

It is possible the evidence exists and I am searching for the wrong term.

What would count as evidence here, and does it exist?

clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

745 questionssemaglutide
semaglutide

A GLP-1 receptor agonist with a fatty-acid-acylated backbone and a roughly one-week half-life, marketed for type 2 diabetes and for weight…

470 questionstirzepatide
tirzepatide

A dual GIP and GLP-1 receptor agonist. Questions here cover the SURPASS and SURMOUNT programmes, the practical differences from a pure GLP-1…

370 questions
shareeditfollowflag
TW
askedtare_weight60k1485 Mar 2026
7Is this the randomised phase or the open-label extension? – Dr_Fatima_Belkacem 8 months ago
add a comment

No answers yet

This question has not been answered. It has been viewed 4.8k times, which suggests the question is of interest and the answer is not obvious. If you can answer it with a source or a worked calculation, it will be read. See how to ask and answer.
Sponsored

Sigma-Aldrich - Certified Reference Materials

Analytical standards and reagents with traceable certificates. Every quantitative result you read inherits the accuracy of the standard behind it.

Shop standards

Your answer

Ask PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.

Not medical advice. Research-use-only compounds are not approved for human use.